Table 3.

Best overall response in relapsed/refractory indolent B-cell lymphoma and DLBCL for single-agent pinatuzumab vedotin

Indolent B-cell lymphomaaDLBCLCLL
<1.8 mg/kg1.8 mg/kg2.4 mg/kg<1.8 mg/kg1.8 mg/kg2.4 mg/kg3.2 mg/kg<1.8 mg/kg1.8 mg/kg2.4 mg/kg
(n = 8)(n = 3)(n = 14)(n = 8)(n = 4)(n = 25)(n = 1)(n = 6)(n = 3)(n = 1)
Complete response003 (21.4%)2 (25.0%)1 (25.0%)4 (16.0%)0000
Partial response01 (33.3%)4 (28.6%)1 (12.5%)1 (25.0%)5 (20.0%)1 (50.0%)000
Stable disease4 (50.0%)2 (66.7%)2 (14.3%)1 (12.5%)0 (0.0%)4 (16.0%)01 (16.7%)1 (33.3%)0
Progressive disease4 (50.0%)(0.0%)3 (21.4%)4 (50.0%)1 (25.0%)11 (44.0%)02 (33.3%)2 (66.7%)0
Unable to evaluateb000001 (4.0%)0000
Missingc002 (14.3%)01 (25.0%)003 (50.0%)01 (100.0%)
  • aIncludes follicular lymphoma, marginal zone lymphoma and small lymphocytic lymphoma. No patients with indolent B-cell lymphoma received pinatuzumab vedotin at 1.8 mg/kg.

  • bScan was done but response could not be determined.

  • cEarly discontinuation prior to scheduled tumor assessment or assessment visit was not reached at the time of data cutoff.